Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche

Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche


Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.

The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market.

Roche shares jumped in early deals and were trading 5.87% higher as of 11:17 a.m. London time.

Shares of Wegovy-maker Novo Nordisk fell 3.77%, while Zepbound producer Eli Lilly was around 2.7% lower in premarket trading.

Shares of Danish biotech company Zealand Pharma, which is also developing its own obesity treatment, were also down more than 5.6%.

Roche said its experimental once-daily pill CT-996 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without Type 2 diabetes in a Phase I trial.

“We are pleased to see the clinically meaningful weight loss in people treated with our oral GLP-1 therapy CT-996, which could eventually help patients address both chronic weight management and glycemic control indications,” Roche’s Chief Medical Officer Levi Garraway said in the Wednesday statement.

The results come as competition mounts in the fast-growing weight loss drug sector, with Roche’s oral pill likely to provide an appealing alternative for patients who dislike injections.

Roche completed its acquisition of anti-obesity drug developer Carmot Therapeutics in January, and in May the firm released promising early-stage data for another one of its weight loss drug candidates, CT-388.

However, Roche Pharmaceuticals CEO Teresa Graham told CNBC in December that it may be several years before the oral obesity treatments are widely available.



Source

IBM is trying to rebound after results disappointed initially. What analysts and investors are saying
World

IBM is trying to rebound after results disappointed initially. What analysts and investors are saying

Analysts remain largely split on IBM ‘s future after the tech stalwart posted key metrics that flashed warning signs heading into 2026. While IBM reported a third-quarter earnings and revenue beat , analysts pointed to metrics below the surface headline beat that might indicate a worrisome near-term setup for the stock: namely, softness in IBM’s […]

Read More
The Beyond Meat fever highlights the risk of trying to ride the meme trade wave
World

The Beyond Meat fever highlights the risk of trying to ride the meme trade wave

The latest frenzy in Beyond Meat is offering a fresh reminder for investors chasing the latest viral stock — Riding the meme wave is fun, until it isn’t. The food company known for its plant-based burgers and sausages experienced monstrous gains of 128% Monday and 146% Tuesday. On Wednesday, the stock erased a triple-digit intraday […]

Read More
Kering shares pop as ‘sharp’ improvement at Gucci builds investor optimism
World

Kering shares pop as ‘sharp’ improvement at Gucci builds investor optimism

A woman wearing a Gucci belt and bag is seen during Paris Fashion Week in September 2018  Christian Vierig | Getty Images Shares of Gucci owner Kering closed up 8.7% on Thursday, hitting a 1-year high after the company’s sales decline narrowed and quarterly earnings beat estimates. The French luxury giant – whose brands include […]

Read More